
Overview
InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and is committed to becoming a global leader in revolutionary cancer therapies.
History
Company founded Tens of millions USD of A round raised Preliminary R&D pipeline established
Opening of InxMed Shanghai & Beijing offices
IN10018 Received US FDA IND Approval
Achieved clinical collaboration with Roche for IN10018 co-development
IN10018 Phase I Clinical Trial in China approved
Achieved clinical collaboration with Merck for IN10018 co-development
Vision
With in-depth knowledge of disease biology at the core of our innovation, InxMed is committed to becoming a global leader in revolutionary cancer therapies


Mission
To invent personalized medicines with a global impact based on our integrated translational R&D platform
Key Contacts
InxMed (Nanjing) Co., Ltd.
ADD: 73 Tanmi Road Block D-2, Jiangbei New District, Nanjing
InxMed(Shanghai)Co., Ltd.
ADD: 515 Huanke Road, Greenland M-Town Tower 1, Room 602-603 Pudong
InxMed (Beijing) Co., Ltd.
ADD: 79 Jianguo Road, China Central Place Tower 2, Room 3007, Chaoyang
InxMed (Austrilia) Co., Ltd.
ADD: 1204, 227 ELIZABETH STREET, SYDNEY, NSW, 2000
Online Message


We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us:
CopyRight © 2022 InxMed All Rights Reserved.